"Head-to-Head: Gilead and AstraZeneca/Daiichi Sankyo Unveil Promising Mid-Stage Results for TROP2 Antibody-Drug Conjugates"

Gilead and AstraZeneca/Daiichi Sankyo have presented preliminary mid-stage data on their rival TROP2 antibody-drug conjugates (ADCs) combined with immune checkpoint inhibitors in non-small cell lung cancer. While Gilead noticed a slightly higher response rate, analysts consider the results to be broadly similar. Both ADCs target the TROP2 receptor and have shown promise in breast cancer and NSCLC, with AstraZeneca's Da­to-DXd in Phase III and Gilead's Trodelvy already approved for certain forms of breast cancer and bladder cancer.